Breaking News Instant updates and real-time market news.

MDCO

The Medicines Co.

$38.51

0.32 (0.84%)

, ALNY

Alnylam

$70.30

1.73 (2.52%)

07:12
10/06/16
10/06
07:12
10/06/16
07:12

Alnylam setback has no read-through to Medicines Co., says Jefferies

Jefferies analyst Biren Amin believes Alnylam Pharmaceuticals' (ALNY) decision to stop revusiran due to lack of a treatment benefit has no read-through to The Medicines Co.'s (MDCO) PCSK9 program. Amin keeps a Buy rating on Medicines Co. with a $43 price target.

MDCO

The Medicines Co.

$38.51

0.32 (0.84%)

ALNY

Alnylam

$70.30

1.73 (2.52%)

  • 14

    Oct

  • 06

    Nov

MDCO The Medicines Co.
$38.51

0.32 (0.84%)

05/13/16
JEFF
05/13/16
NO CHANGE
Target $43
JEFF
Buy
The Medicines Co. could rally $4/share on positive data, says Jefferies
Jefferies analyst Biren Amin says The Medicines Co. has a "catalyst-rich" second half of 2016, including the Phase III trials of Carbavance in complicated urinary tract infections and carbapenem resistant enterobacteriaceae infections. The analyst expects both of the trials will be successful and show non-inferiority leading to potential FDA approval. Amin thinks shares could move $3 to $4 per share on positive data readout. He keeps a Buy rating on The Medicines Co. with a $43 price target.
07/11/16
JEFF
07/11/16
NO CHANGE
Target $43
JEFF
Buy
Jefferies views The Medicines Co. ruling as positive surprise
Jefferies analyst Biren Amin views today's Court of Appeals ruling as a "positive surprise" for The Medicines Company. The ruling "breathes potential life" into the company's Angiomax patents, Amin tells investors in a research note. He expects Hospira to file an appeal within 90 days. The analyst has a Buy rating on The Medicines Co. with a $43 price target.
08/02/16
EVER
08/02/16
NO CHANGE
EVER
Buy
Pfizer shelves oral PCSK9, a Medicines Co. competitor, says Evercore ISI
Evercore ISI analyst Umer Raffat said Pfizer (PFE) management does not thin the profile for oral PCSK9 will be competitive with the strong efficacy of antibodies and have moved other interesting products forward. Raffat said some Medicines Co. (MDCO) investors had worried that a potential oral PCSk9 from Pfizer could greatly reduce enthusiasm for an every-6-month PCSk9 from MDCO. The analyst said the next catalyst for The Medicines Co. is A1 Milano readout this month. Raffat rates The Medicines Co. a Buy with a $52 price target.
09/09/16
LEER
09/09/16
NO CHANGE
LEER
Leerink updates therapeutics best ideas for 2016
In a note to investors this morning, Leerink has updated its best ideas for 2016 from the firm's five therapeutics analysts. The list includes Alexion (ALXN), Dermira (DERM), Intra-Cellular (ITCI), Sanofi (SNY), Allergan (AGN), Alnylam (ALNY), Innate Pharma (IPHYF), The Medicines Co. (MDCO), and Ophthotech (OPHT).
ALNY Alnylam
$70.30

1.73 (2.52%)

10/06/16
JPMS
10/06/16
DOWNGRADE
Target $51
JPMS
Neutral
Alnylam downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Anupam Rama downgraded Alnylam Pharmaceuticals to Neutral after the company said it will discontinue Revusiran for the treatment of Familial Amyloid Cardiomyopathy. The analyst viewed the drug as a "key asset" and cut his price target for the shares to $51 from $83. Barclays this morning also downgraded Alnylam.
10/06/16
PIPR
10/06/16
NO CHANGE
Target $106
PIPR
Overweight
Alnylam selloff a buying opportunity, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff views today's selloff in shares of Alnylam Pharmaceuticals after the company discontinued its revusiran program as a buying opportunity. The analyst does not believe the discontinuation has read-through to the Phase III APOLLO trial or seven other RNAi drugs that employ ESC-GalNAc technology. He lowered his price target for Alnylam shares to $106 from $118 and keeps an Overweight rating on the name. JPMorgan and Barclays this morning downgraded the shares.
10/06/16
LEER
10/06/16
DOWNGRADE
Target $40
LEER
Market Perform
Alnylam downgraded to Market Perform from Outperform at Leerink
Leerink analyst Michael Schmidt downgraded Alnylam Pharmaceuticals to Market Perform after the company discontinued development of revusiran. To reflect an increased level of uncertainty around the company's pipeline, the analyst cut his price target for the shares to $40 from $107. JPMorgan and Barclays also downgraded Alnylam this morning while Piper Jaffray recommends buying the stock on weakness.
10/06/16
PIPR
10/06/16
NO CHANGE
Target $46
PIPR
Overweight
Piper thinks Alnylam failure is positive for Ionis
Piper Jaffay analyst Joshua Schimmer thinks Alnylam Pharmaceuticals' (ALNY) "abrupt halt" of revusiran for TTR cardiomyopathy is likely a positive for Ionis Pharmaceuticals' (IONS) transthyretin program. The move "knocks out a competitive drug" while Ionis and GlaxoSmithKline (GSK) remain on their previously indicated timeline, Schimmer tells investors in a research note. The analyst at this point believes Alnylam's setback will be limited to revusiran and not read-through to other Gal-Nac programs or other TTR cardiomyopathy or polyneuropathy programs. He keeps an Overweight rating on Ionis with a $46 price target,

TODAY'S FREE FLY STORIES

14:20
09/26/17
09/26
14:20
09/26/17
14:20
Conference/Events
FBN Securities strategist to hold an analyst/industry conference call »

Chief Market Strategist…

BLK

BlackRock

$434.46

-3.17 (-0.72%)

14:20
09/26/17
09/26
14:20
09/26/17
14:20
Options
Far upside call buyer in Blackrock opens a notable new position »

Far upside call buyer in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

  • 22

    Oct

SYT

Syngenta

$92.07

-0.01 (-0.01%)

14:18
09/26/17
09/26
14:18
09/26/17
14:18
Hot Stocks
Syngenta reports pending settlement to resolve corn litigation »

Plaintiffs and defendants…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

14:17
09/26/17
09/26
14:17
09/26/17
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

14:16
09/26/17
09/26
14:16
09/26/17
14:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DAL

Delta Air Lines

$48.42

0.1 (0.21%)

14:10
09/26/17
09/26
14:10
09/26/17
14:10
Options
Delta calls outpace puts 10:1 as a bullish spread is opened »

Delta calls outpace puts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MOH

Molina Healthcare

$65.78

1.24 (1.92%)

, UNH

UnitedHealth

$192.38

0.63 (0.33%)

14:09
09/26/17
09/26
14:09
09/26/17
14:09
Periodicals
GOP agrees not to vote on healthcare bill, CNN reports »

Senate Majority Leader…

MOH

Molina Healthcare

$65.78

1.24 (1.92%)

UNH

UnitedHealth

$192.38

0.63 (0.33%)

CNC

Centene

$92.15

1.82 (2.01%)

WCG

WellCare

$165.88

1.7305 (1.05%)

CI

Cigna

$183.10

1.66 (0.91%)

ANTM

Anthem

$183.18

1.68 (0.93%)

HNT

Health Net

HUM

Humana

$239.83

2.62 (1.10%)

AET

Aetna

$153.66

1.6785 (1.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 26

    Sep

  • 27

    Sep

  • 04

    Oct

  • 17

    Oct

  • 24

    Oct

  • 08

    Nov

FL

Foot Locker

$34.77

0.11 (0.32%)

14:05
09/26/17
09/26
14:05
09/26/17
14:05
Options
Foot Locker call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AXP

American Express

$88.48

0.27 (0.31%)

13:58
09/26/17
09/26
13:58
09/26/17
13:58
Hot Stocks
American Express raises quarterly dividend 9% to 35c per share »

The board of directors of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

  • 18

    Oct

  • 22

    Oct

FIT

Fitbit

$6.49

0.045 (0.70%)

13:57
09/26/17
09/26
13:57
09/26/17
13:57
Hot Stocks
Fitbit to participate in FDA software pilot program »

Fitbit announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 11

    Dec

FB

Facebook

$162.87

-7.67 (-4.50%)

, WMT

Wal-Mart

$79.48

0.33 (0.42%)

13:51
09/26/17
09/26
13:51
09/26/17
13:51
Hot Stocks
Wal-Mart to roll out Workplace by Facebook »

Julien Codorniou, the VP…

FB

Facebook

$162.87

-7.67 (-4.50%)

WMT

Wal-Mart

$79.48

0.33 (0.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 03

    Oct

  • 08

    Oct

  • 10

    Oct

  • 22

    Oct

  • 16

    Nov

  • 21

    Nov

  • 20

    Feb

PTEN

Patterson-UTI

$20.47

0.94 (4.81%)

13:50
09/26/17
09/26
13:50
09/26/17
13:50
Options
Put buyers active in Patterson Energy »

Put buyers active in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$162.87

-7.67 (-4.50%)

, SLF

Sun Life Financial

$39.46

0.19 (0.48%)

13:49
09/26/17
09/26
13:49
09/26/17
13:49
Hot Stocks
Sun Life Financial announces launch of Workplace by Facebook »

Sun Life Financial (SLF)…

FB

Facebook

$162.87

-7.67 (-4.50%)

SLF

Sun Life Financial

$39.46

0.19 (0.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

  • 03

    Oct

  • 08

    Oct

  • 22

    Oct

ELF

e.l.f. Beauty

$19.68

-0.025 (-0.13%)

, WBA

Walgreens Boots Alliance

$78.96

0.55 (0.70%)

13:46
09/26/17
09/26
13:46
09/26/17
13:46
Recommendations
e.l.f. Beauty, Walgreens Boots Alliance analyst commentary  »

e.l.f. Beauty products…

ELF

e.l.f. Beauty

$19.68

-0.025 (-0.13%)

WBA

Walgreens Boots Alliance

$78.96

0.55 (0.70%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

13:45
09/26/17
09/26
13:45
09/26/17
13:45
General news
Fed funds futures slid lower on the heels of Yellen's comments »

Fed funds futures slid…

SRCI

SRC Energy

$9.18

0.36 (4.08%)

13:40
09/26/17
09/26
13:40
09/26/17
13:40
Options
Call writer opens a notable new position in SRC Energy as shares outperform »

Call writer opens a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 16

    May

HMNY

Helios and Matheson

$8.30

1.33 (19.08%)

13:40
09/26/17
09/26
13:40
09/26/17
13:40
Periodicals
Helios and Matheson mentioned cautiously by TheStreetSweeper 

Reference Link

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDP

Meredith

$54.05

-0.35 (-0.64%)

13:31
09/26/17
09/26
13:31
09/26/17
13:31
Hot Stocks
Meredith names Alysia Borsa chief marketing and data officer »

Meredith Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BWP

Boardwalk Pipeline

$14.95

0.1734 (1.17%)

13:30
09/26/17
09/26
13:30
09/26/17
13:30
Options
In the money call buying continues in Boardwalk Pipeline »

In the money call buying…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:30
09/26/17
09/26
13:30
09/26/17
13:30
General news
More from Yellen: not much new in her Q&A, reiterating the two sided risks »

More from Yellen: not…

NKE

Nike

13:29
09/26/17
09/26
13:29
09/26/17
13:29
Periodicals
Nike: Code left company over 3 years ago, no longer an employee, Bloomberg says »

Merl Code, the former…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 03

    Oct

  • 04

    Oct

  • 10

    Oct

13:20
09/26/17
09/26
13:20
09/26/17
13:20
General news
Treasury Action: yields steadied below highs »

Treasury Action: yields…

$NSD

NASDAQ Market Internals

13:17
09/26/17
09/26
13:17
09/26/17
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

13:16
09/26/17
09/26
13:16
09/26/17
13:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TGT

Target

$58.49

-0.06 (-0.10%)

13:15
09/26/17
09/26
13:15
09/26/17
13:15
Conference/Events
Target management to meet with Jefferies »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 27

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.